MET-3 is under clinical development by Nubiyota and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MET-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MET-3 overview
MET-3 is under development for the treatment of hypertriglyceridemia. It comprises live microbiota that normally reside in the human gut of a healthy individual. It is administered through oral route as a lyophilized capsule. The drug candidate is being developed based on Microbial Ecosystem Therapeutics (MET) technology.
It was also under development for obesity.
Nubiyota overview
Nubiyota operates within the pharmaceuticals and healthcare industry, specifically focusing on the therapy area of gastrointestinal disorders, with a specialization in ulcerative colitis, a type of inflammatory bowel disease. The company is headquartered in Pearl River, New York, the US.
For a complete picture of MET-3’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
